Ketan Mehta Net Worth

Ketan Mehta biography

Ketan Bhupatrai Mehta serves as Director of the Company. Mr. Mehta, a pharmaceutical scientist by education, is the Founder and Chief Executive Officer of Tris Pharma, a fully-integrated specialty pharmaceutical company focused on developing and commercializing advanced delivery technologies. Mr. Mehta founded Tris in 2000 and has built the company into a leading specialty pharmaceutical company with over 500 employees. Tris develops, manufactures, licenses, and commercializes both branded and generic pharmaceuticals directly and through commercial partnerships with both large and emerging pharmaceutical companies. Tris has developed many pharmaceutical technologies, including its extended-release platform LiquiXR® and holds over 150 patents in the U.S. and around the world. Before founding Tris Pharma, Mr. Mehta worked for Capsugel (formerly a division of Pfizer) in sales, marketing and business development for eight years. Prior to Capsugel, he spent approximately six years as a pharmaceutical scientist for three different large pharmaceutical companies. Mr. Mehta holds an MS degree in Pharmaceutical Sciences from the University of Oklahoma.

What is the salary of Ketan Mehta?

As the Director of Aytu BioPharma Inc, the total compensation of Ketan Mehta at Aytu BioPharma Inc is $99,018. There are 8 executives at Aytu BioPharma Inc getting paid more, with Joshua Disbrow having the highest compensation of $1,043,700.

How old is Ketan Mehta?

Ketan Mehta is 58, he's been the Director of Aytu BioPharma Inc since 2018. There are 2 older and 9 younger executives at Aytu BioPharma Inc. The oldest executive at Aytu BioPharma Inc is Michael Macaluso, 67, who is the Independent Director.

What's Ketan Mehta's mailing address?

Ketan's mailing address filed with the SEC is , 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD, CO, 80112.

Insiders trading at Aytu BioPharma Inc

Over the last 9 years, insiders at Aytu BioPharma Inc have traded over $40,722,795 worth of Aytu BioPharma Inc stock and bought 8,465,326 units worth $11,497,374 . The most active insiders traders include Capital, Llc Armistice Capi..., Carl Dockery, and Joshua R. Disbrow. On average, Aytu BioPharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $2,701,531. The most recent stock trade was executed by Greg Pyszczymuka on 30 June 2024, trading 208 units of AYTU stock currently worth $522.

What does Aytu BioPharma Inc do?

aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.

Aytu BioPharma Inc executives and stock owners

Aytu BioPharma Inc executives and other stock owners filed with the SEC include:

• Joshua Disbrow,
  Chairman of the Board, Chief Executive Officer
• Joshua R. Disbrow,
  Chairman & CEO
• Jarrett Disbrow,
  Chief Operating Officer
• David Green,
  Chief Financial Officer, Treasurer, Secretary
• Michael Macaluso,
  Independent Director
• John Donofrio,
  Independent Director
• Carl Dockery,
  Independent Director
• Gary Cantrell,
  Independent Director
• Ketan Mehta,
  Director
• James Carbonara,
  IR Contact Officer
• Steven Boyd,
  Director
• Matthew Phillips,
  Executive Vice President - Commercial Operations
• Russ McMahen,
  Sr. VP of R&D
• Topher Brooke,
  Exec. VP of Rare Disease Devel.
• Nate Massari,
  Exec. VP of Rare Disease Operations
• Greg Pyszczymuka,
  Chief Commercial Officer
• Jarrett T. Disbrow Ph.D.,
  Exec. VP of Corp. Operations
• Beth Hecht,
  Director
• Gerald W. Mc Laughlin,
  Director
• Inc. Cerecor,
  10% owner
• Capital Management, Llc Har...,
  
• Gregory A Gould,
  Chief Financial Officer
• Jonathan H Mc Grael,
  Vice President of Sales
• Pharmaceuticals, Inc. Ampio,
  10% owner
• Mark K Oki,
  Chief Financial Officer
• Greg Pyszczymuka,
  Chief Commercial Officer
• Christopher Brooke,
  Chief Operating Officer
• Abhinav Jain,
  
• Vivian H Liu,
  
• Richard I Eisenstadt,
  Chief Financial Officer